EGFR and non-small cell lung carcinoma: The latest advance of phase 3 trials ADAURA study (NCT02511106) confirmed Adjuvant osimertinib could get a significant 85% 5‐year OS benefit among patients with completely resected, EGFR‐mutated, stage IB to IIIA NSCLC, showing the powerful therapy efficiency of targeted therapy.29